[Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?]
Revidierte Fassung der S3-Leitlinie Zervixkarzinom 2021 – Anforderungen an die Pathologie.
Cutting
Diagnostic
Workup
Journal
Pathologie (Heidelberg, Germany)
ISSN: 2731-7196
Titre abrégé: Pathologie (Heidelb)
Pays: Germany
ID NLM: 9918384887506676
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
25
10
2021
pubmed:
23
2
2022
medline:
9
8
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
In 2021, the 2015 German consensus guideline for the diagnosis and treatment of uterine cervical carcinoma was updated. The present article summarises the new recommendations for pathologists: the incorporation of the International Endocervical Adenocarcinoma Classification (IECC), which morphologically separates HPV-associated and non-HPV-associated adenocarcinomas, as well as the reporting of the prognostic relevant growth pattern of the adenocarcinoma of the endocervical subtype (Silva pattern). Histologically, multifocality has been defined as the presence of clearly invasive foci with a minimum distance between each focus of 0.2 cm. Because of its intratumoural heterogeneity, all carcinomas ≤ 2 cm in their largest dimension should be processed completely, and tumours > 2 cm should be processed with one block per centimetre of their greatest dimension. In cases of (radical) trachelectomy/hysterectomy, the distal vaginal resection margin and all parametrial tissue should be processed completely. Sentinel lymph nodes have to be processed completely by lamellation along its long axis in 0.2 cm intervals. Immunohistochemical ultrastaging is mandatory. Staging should be performed using the 2009 FIGO classification and 2017 TNM classification. Reporting the revised 2018 FIGO classification is optional. To date, molecular markers have not been relevant for prognostication and treatment decision making. Im Jahr 2015 wurde die S3-Leitlinie für Diagnostik und Therapie des Zervixkarzinoms erstellt, die 2021 in ihrer revidierten Fassung vorliegt. Neu für die Pathologie sind die Aufnahme der International Endocervical Adenocarcinoma Classification (IECC), die zwischen HPV-assoziierten und non-HPV-assoziierten Karzinomen unterschiedet, sowie des prognostisch relevanten morphologischen Wachstumsmusters bei (HPV-assoziierten) Adenokarzinomen (sog. Silva-Pattern). Die Multifokalität beim mikroinvasiven Zervixkarzinom ist nun definiert als der Nachweis voneinander histologisch klar separierter invasiver Foci mit einem minimalen Abstand von 0,2 cm. Aufgrund einer möglichen intratumoralen Heterogenität sollen Zervixkarzinome ≤ 2 cm vollständig und Tumoren > 2 cm mit einem Block pro Zentimeter größter Ausdehnung eingebettet werden. Bei der (radikalen) Trachelektomie/Hysterektomie sollen der vaginale Resektionsrand und das parametrane Gewebe vollständig eingebettet werden. Neu ist die Empfehlung zur Aufarbeitung von Sentinellymphknoten. Diese sollen entlang ihrer Längsachse in 0,2 cm Abstand lamelliert, vollständig eingebettet und mittels Ultrastaging aufgearbeitet werden. Die FIGO-Klassifikation von 2009 bzw. TNM-Kategorisierung von 2017 wird beibehalten, die Angabe der FIGO-Klassifikation 2018/19 ist optional. Molekulare Marker spielen derzeit noch keine relevante Rolle in der Prognose und zum Therapieentscheid.
Autres résumés
Type: Publisher
(ger)
Im Jahr 2015 wurde die S3-Leitlinie für Diagnostik und Therapie des Zervixkarzinoms erstellt, die 2021 in ihrer revidierten Fassung vorliegt. Neu für die Pathologie sind die Aufnahme der International Endocervical Adenocarcinoma Classification (IECC), die zwischen HPV-assoziierten und non-HPV-assoziierten Karzinomen unterschiedet, sowie des prognostisch relevanten morphologischen Wachstumsmusters bei (HPV-assoziierten) Adenokarzinomen (sog. Silva-Pattern). Die Multifokalität beim mikroinvasiven Zervixkarzinom ist nun definiert als der Nachweis voneinander histologisch klar separierter invasiver Foci mit einem minimalen Abstand von 0,2 cm. Aufgrund einer möglichen intratumoralen Heterogenität sollen Zervixkarzinome ≤ 2 cm vollständig und Tumoren > 2 cm mit einem Block pro Zentimeter größter Ausdehnung eingebettet werden. Bei der (radikalen) Trachelektomie/Hysterektomie sollen der vaginale Resektionsrand und das parametrane Gewebe vollständig eingebettet werden. Neu ist die Empfehlung zur Aufarbeitung von Sentinellymphknoten. Diese sollen entlang ihrer Längsachse in 0,2 cm Abstand lamelliert, vollständig eingebettet und mittels Ultrastaging aufgearbeitet werden. Die FIGO-Klassifikation von 2009 bzw. TNM-Kategorisierung von 2017 wird beibehalten, die Angabe der FIGO-Klassifikation 2018/19 ist optional. Molekulare Marker spielen derzeit noch keine relevante Rolle in der Prognose und zum Therapieentscheid.
Identifiants
pubmed: 35191993
doi: 10.1007/s00292-021-01051-3
pii: 10.1007/s00292-021-01051-3
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
292-302Informations de copyright
© 2022. The Author(s).
Références
Alvarado-Cabrero I et al (2019) Micropapillary cervical adenocarcinoma: a clinicopathologic study of 44 cases. Am J Surg Pathol 43(6):802–809
pubmed: 30864975
pmcid: 8258798
Andikyan V et al (2014) Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: Is less enough? Int J Gynecol Cancer 24(1):113–117
pubmed: 24335661
pmcid: 4972180
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Mäenpää J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135
pubmed: 30656645
Bosse T et al (2015) Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742–1750
pubmed: 26049688
Brambs CE et al (2019) The prognostic impact of grading in FIGO IB and IIB squamous cell cervical carcinomas. Geburtshilfe Frauenheilkd 79(2):198–204
pubmed: 30792550
pmcid: 6379165
Burk RD, Cancer Genome Atlas Research Network (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543(7645):378–384
College of American Pathologists (2013) Protocol for the examination of specimens from patients withcarcinoma of the uterine cervix. http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/Cervix_13protocol_3210.pdf . Zugegriffen: 9. Juni 2021
Cibula D et al (2018) The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer 28(4):641–655
pubmed: 29688967
Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet 393(10167):169–182
pubmed: 30638582
Day E, Duffy S, Bryson G, Syed S, Shanbhag S, Burton K, Lindsay R, Siddiqui N, Millan D (2016) Multifocal FIGO stage IA1 squamous carcinoma of the cervix: criteria for identification, staging, and its good clinical outcome. Int J Gynecol Pathol 35(5):467–474
pubmed: 26863478
ESGO (2018) ESGO/ESTRO/ESP—guidelines for cervical carcinoma. https://guidelines.esgo.org/media/2018/04/Cervical-cancer-Guidelines-Complete-report.pdf . Zugegriffen: 9. Juni 2021
Euscher ED et al (2008) Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. Am J Surg Pathol 32(9):1336–1343
pubmed: 18670356
Gadducci A, Guerrieri ME, Cosio S (2019) Adenocarcinoma of the uterine cervix: pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol Hematol 135:103–114
pubmed: 30819439
Ganesan R et al (2016) Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome. Int J Surg Pathol 24(6):490–496
pubmed: 27098591
Guani B et al (2019) Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL trial. Int J Gynecol Cancer 29(3):447–452
pubmed: 30833435
Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD, Jordanova ES (2016) Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 29(7):753–763
pubmed: 27056074
pmcid: 4931542
Hirschowitz L, Sen C, Murdoch J (2007) Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia—a potential diagnostic pitfall. Diagn Pathol 2:40
pubmed: 17961245
pmcid: 2116996
Hodgson A et al (2019) International endocervical adenocarcinoma criteria and classification: validation and interobserver reproducibility. Am J Surg Pathol 43(1):75–83
pubmed: 29877920
pmcid: 6281796
Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D, German Cancer Society (2015) S3-Leitlinie Diagnostik und Therapie des Zervixkarzinoms. Pathologe 36(6):585–593
pubmed: 26483249
Horn LC, Höhn AK (2017) Processing and histopathological workup of hysterectomy specimens. Springer Nature,
Horn LC et al (2005) Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies. Pathologe 26(4):266–272
pubmed: 15915329
Horn LC et al (2006) Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index. Ann Diagn Pathol 10(3):140–143
pubmed: 16730307
Horn LC et al (2014) A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer. Gynecol Oncol 134(1):42–46
pubmed: 24768850
Horn LC et al (2016) Grading of gynecological tumors: current aspects. Pathologe 37(4):337–351
pubmed: 27379622
Horn LC et al (2019) The 2019 FIGO classification for cervical carcinoma—what’s new? Pathologe 40(6):629–635
pubmed: 31612260
Horn LC et al (2019) Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma. J Cancer Res Clin Oncol 145(10):2573–2582
pubmed: 31385027
Horn LC et al (2019) Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas. J Cancer Res Clin Oncol 145(2):457–462
pubmed: 30603900
Jesinghaus M et al (2018) Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. J Pathol Clin Res 4(2):93–102
pubmed: 29665323
pmcid: 5903696
Kaliff M, Karlsson MG, Sorbe B, Bohr Mordhorst L, Helenius G, Lillsunde-Larsson G (2020) HPV-negative tumors in a Swedish cohort of cervical cancer. Int J Gynecol Pathol 39(3):279–288
pubmed: 31206367
Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA, Park KJ (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39(11):1449–1457
pubmed: 26457350
pmcid: 4976691
Kim CH et al (2013) Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 23(5):964–970
pubmed: 23694985
pmcid: 4079038
Lapuz C, Kondalsamy-Chennakesavan S, Bernshaw D, Khaw P, Narayan K (2016) Stage IB cervix cancer with nodal involvement treated with primary surgery or primary radiotherapy: patterns of failure and outcomes in a contemporary population. J Med Imaging Radiat Oncol 60(2):274–282
pubmed: 26549207
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Leath CA 3rd, Monk BJ (2018) Twenty-first century cervical cancer management: a historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150(3):391–397
Marret G, Borcoman E, Le Tourneau C (2019) Pembrolizumab for the treatment of cervical cancer. Expert Opin Biol Ther 19(9):871–877
pubmed: 31322926
Matsuo K et al (2019) Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol 152(1):87–93
pubmed: 30389105
Mayr D, Schmoeckel E, Höhn AK, Hiller GGR, Horn LC (2021) Aktuelle WHO-Klassifikation des weiblichen Genitale: Viel Neues, aber auch manch Altes. Pathologe 42(3):259–269
pubmed: 33822250
McCluggage WG et al (2018) Data set for the reporting of carcinomas of the cervix: recommendations from the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol 37(3):205–228
pubmed: 28700433
McIlwaine P, Nagar H, McCluggage WG (2014) Multifocal FIGO stage 1A1 cervical squamous carcinomas have an extremely good prognosis equivalent to unifocal lesions. Int J Gynecol Pathol 33(3):213–217
pubmed: 24681729
Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L (2018) PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 9(16):2938–2945
pubmed: 30123362
pmcid: 6096364
Minion LE, Tewari KS (2018) Cervical cancer—state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 148(3):609–621
pubmed: 29666026
pmcid: 6720107
Mirkovic J et al (2015) Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol 28(11):1504–1514
pubmed: 26336887
Morgan S, Slodkowska E, Parra-Herran C, Mirkovic J (2019) PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix. Histopathology 74(7):997–1004
pubmed: 30667073
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabiño NB, Gómez-Macías GS, Valdez-Chapa LD, Garza-Rodríguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldaña HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506(7488):371–375
pubmed: 24390348
Omori M, Hashi A, Kondo T, Katoh R, Hirata S (2015) Dysregulation of CDK inhibitors and p53 in HPV-negative endocervical adenocarcinoma. Int J Gynecol Pathol 34(2):196–203
pubmed: 25675191
Ondič O, Němcová J, Alaghehbandan R, Černá K, Gomolčáková B, Kinkorová-Luňáčková I, Chytra J, Šidlová H, Májek O, Bouda J (2019) The detection of DNA methylation of tumour suppressor genes in cervical high-grade squamous intraepithelial lesion: a prospective cytological-histological correlation study of 70 cases. Cytopathology 30(4):426–431
pubmed: 31074057
Park HM et al (2009) Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix: a case report. J Korean Med Sci 24(4):767–771
pubmed: 19654969
pmcid: 2719211
Parra-Herran C, Alvarado-Cebrero I, Hoang LN, Kiyokawa T, Kong CS, Park KJ, Stolnicu S, Zannoni (2020) Adenocarcinoma, HPV-associated of the uterine cervix. In: WHO classification of tumours of the female genital tract. IARC, Lyon, S 367–371
Peters EEM et al (2019) Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology 75(1):128–136
pubmed: 31155736
pmcid: 6852322
Rasty G, Hauspy J, Bandarchi B (2009) Assessment of sentinel lymph node in cervical cancer: review of literature. J Clin Pathol 62(12):1062–1065
pubmed: 19748910
Reich O, Pickel H (2002) Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions. Int J Gynecol Pathol 21(4):416–417
pubmed: 12352192
Roma AA, Fadare O (2018) The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. Virchows Arch 472(6):897–905
pubmed: 29404709
Roma AA et al (2015) Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance. Am J Surg Pathol 39(5):667–672
pubmed: 25724003
Roma AA et al (2016) New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol 141(1):36–42
pubmed: 27016227
pmcid: 5068220
Roszik J et al (2018) Gene expression analysis identifies novel targets for cervical cancer therapy. Front Immunol 9:2102
pubmed: 30283446
pmcid: 6156434
Roy M et al (2011) Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol 122(2):269–274
pubmed: 21529908
Saco A, Carrilho C, Focchi GRA, Kong CS, Mills AM, Park KJ, Regauer S (2020) Squamous cell carcinoma, of the uterine cervix. In: WHO classification of tumours of the female genital tract. IARC, Lyon, S 347–350
Satabongkoch N et al (2017) Prognostic value of tumor budding in early-stage cervical adenocarcinomas. Asian Pac J Cancer Prev 18(6):1717–1722
pubmed: 28670894
pmcid: 6373798
Singh N, Gilks CB (2017) The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. Histopathology 70(1):56–69
pubmed: 27960241
Stolnicu S et al (2019) Clinical outcomes of HPV-associated and unassociated endocervical adenocarcinomas categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol 43(4):466–474
pubmed: 30720532
pmcid: 6417947
Stolnicu S et al (2020) Invasive stratified mucinous carcinoma (iSMC) of the cervix often presents with high-risk features that are determinants of poor outcome: an international multicenter study. Am J Surg Pathol 44(10):1374–1380
pubmed: 32271191
pmcid: 7492372
Stolnicu S et al (2018) Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV. Gynecol Oncol 150(1):56–60
pubmed: 29859673
pmcid: 6615482
Stolnicu S, Hoang L, Soslow RA (2019) Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch 475(5):537–549
pubmed: 31209635
pmcid: 6864265
Tewari KS et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734–743
pubmed: 24552320
pmcid: 4010094
Vercellino GF, Erdemoglu E, Lichtenberg P, Muallem MZ, Richter R, Abu-Rustum NR, Plante M, Lécuru F, Greggi S, Monk BJ, Sagae S, Denkert C, Keller M, Alhakeem M, Hellriegel M, Dückelmann AM, Chiantera V, Sehouli J (2019) A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer. Arch Gynecol Obstet 300(1):191–199
pubmed: 31006839
pmcid: 7469255
Wagner AE et al (2013) Impact of tumor size on survival in cancer of the cervix and validation of stage IIA1 and IIA2 subdivisions. Gynecol Oncol 129(3):517–521
pubmed: 23528928
WHO (2020) WHO classification of tumours of the femal genital tract. IARC, Lyon
Wittekind C et al (2012) TNM supplement. A comentary on uniform use. Wiley-Blackwell, London
Wittekind C (2020) TNM Klassifikation maligner Tumoren – Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019. Wiley-VCH, Weinheim
Wittekind C (2017) TNM Klassifikation maligner Tumoren. Wiley-VCH, Weinheim
Wright AA et al (2013) Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119(21):3776–3783
pubmed: 24037752
Wright JD et al (2019) Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol 134(1):49–57
pubmed: 31188324
pmcid: 7641496